Articles
Blog
Evidence-based articles on peptide research, safety, and therapy.
BPC-157: What the Research Actually Shows About This Healing Peptide
BPC-157, a synthetic peptide derived from human gastric juice, has attracted significant research interest for its potential role in tissue healing and recovery. Here is what the evidence actually shows.
Read article →What Are Peptides? A Beginner's Guide to Peptide Science
Peptides are short chains of amino acids that play critical roles in biological signaling. This beginner's guide covers what peptides are, how they function, the major categories of research peptides, and how to evaluate the latest peptide science.
Read article →BPC-157 vs TB-500: Comparing Two Popular Recovery Peptides
BPC-157 and TB-500 are among the most discussed recovery peptides in research communities. This article compares their origins, mechanisms, and the evidence behind each.
Read article →Peptide Therapy: What It Is, How It Works, and What to Expect
Peptide therapy is a growing area of clinical interest. This guide covers what it involves, how peptides are administered, how to find qualified providers, and what to expect.
Read article →Peptide Safety: Understanding Side Effects, Risks, and Research Limitations
Safety is paramount when evaluating any research compound. This guide covers known side effects, quality risks, research limitations, and important safety considerations for peptides.
Read article →How to Reconstitute Peptides: A Complete Guide
Reconstituting lyophilized peptides is one of the most important — and most commonly misunderstood — steps in peptide research. This guide walks through the entire process, from choosing the right solvent to reading syringe markings accurately.
Read article →Understanding Peptide Half-Lives: Why Timing Matters
A peptide's half-life determines how long it remains active in the body and directly dictates optimal dosing frequency. Understanding this concept is essential for designing effective research protocols.
Read article →GLP-1 Peptides and Muscle Preservation: The Protein Connection
GLP-1 receptor agonists produce impressive weight loss, but up to 40% of that loss can come from lean tissue. Understanding the protein connection is critical for preserving muscle mass during treatment.
Read article →FDA Peptide Reclassification 2026: Which Peptides Are Coming Back
In February 2026, HHS Secretary Kennedy announced that peptides would return to compounding access. On April 15, 2026, the FDA made it formal: 12 peptides were removed from Category 2. But removal from Category 2 is not the same as authorization to compound — here is what actually changed, what is still prohibited, and what the July 23-24, 2026 PCAC review will determine.
Read article →FDA Proposes 503B Bulks List Exclusion for Semaglutide, Tirzepatide, and Liraglutide (April 30, 2026)
On April 30, 2026, the FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List. This closes the last remaining legal pathway for outsourcing facilities to mass-compound these GLP-1s — a development distinct from the April 23 reclassification of healing peptides, and one that may reshape access for compounded weight-loss medications. Comment period open through June 29, 2026.
Read article →Retatrutide: The Triple Agonist Peptide Outperforming Semaglutide and Tirzepatide
Retatrutide is a synthetic peptide developed by Eli Lilly that simultaneously activates three receptors: GLP-1, GIP, and glucagon. Phase 2 trials reported 24.2% mean body weight reduction at 48 weeks. Phase 3 TRIUMPH-4 in adults with obesity and knee osteoarthritis subsequently reported up to 28.7% mean weight loss at 68 weeks alongside a 75.8% reduction in WOMAC knee pain. As of May 2026, retatrutide is not FDA-approved and is not available through any channel outside of clinical trial participation.
Read article →Orforglipron vs. Oral Semaglutide: Two GLP-1 Pills, Two Completely Different Technologies
In early 2026, two oral GLP-1 receptor agonists reached wide availability — but they work through fundamentally different mechanisms. Oral semaglutide is a peptide requiring an absorption enhancer and strict fasting protocols. Orforglipron (Foundayo), FDA-approved April 1, 2026, is not a peptide at all: it is a small molecule that binds the same receptor through a chemically stable, orally bioavailable structure. Understanding this distinction illuminates something important for anyone studying peptide pharmacology.
Read article →Foundayo (Orforglipron): Clinical Evidence, Dosing, and Safety Profile
On April 1, 2026, the FDA approved Foundayo (orforglipron) — the first oral, non-peptide GLP-1 receptor agonist for chronic weight management. This evidence summary covers the ATTAIN-1 Phase 3 trial results, mechanism of action, FDA-labeled dosing, the full safety profile, and how Foundayo compares to injectable GLP-1 agonists. Editorial note: orforglipron is a small-molecule drug, not a peptide — we cover it here for context on the broader GLP-1 landscape.
Read article →How Oral Semaglutide Works: The Science of Getting a Peptide Through the Gut
Peptides face a fundamental barrier to oral delivery: the gastrointestinal tract evolved specifically to destroy them. Oral semaglutide is the first commercially successful oral peptide drug, reaching patients at scale in 2026. The mechanism that makes it work — SNAC absorption enhancement — is a genuine scientific achievement, and understanding it illuminates why oral delivery remains one of the hardest problems in peptide pharmacology.
Read article →BPC-157 in 2026: An Honest Assessment of What the Evidence Actually Shows
BPC-157 has accumulated one of the most enthusiastic research communities of any peptide compound, backed by decades of animal studies suggesting potential for tissue repair, gut healing, and neuroprotection. It also returned to legal compounding access in February 2026 after a period of FDA restriction. What is often missing from discussions of BPC-157 is an honest accounting of where the evidence actually stands — which is rich in preclinical signal and nearly empty in human clinical data. Understanding that gap is the whole point.
Read article →Icotrokinra: How a Cyclic Peptide Achieves Oral Delivery Without an Absorption Enhancer
FDA-approved in March 2026, icotrokinra (ICOTYDE) is the first cyclic macropeptide to reach patients orally — no absorption enhancer required. Its ring architecture physically prevents the protease degradation that makes linear peptides injectable-only. Understanding how it works completes a mechanistic picture of the three distinct strategies now available for oral delivery of drugs that mimic peptide signaling.
Read article →How GLP-1 Peptides Work: The Complete Science Behind Semaglutide and Tirzepatide
GLP-1 receptor agonists have become the most prescribed peptide drugs in history. Here is how they work at the molecular level — from the 30-amino-acid hormone secreted by intestinal L-cells to the engineered analogs that resist enzymatic breakdown and last a full week in circulation.
Read article →Semaglutide vs Tirzepatide: How These GLP-1 Weight Loss Peptides Compare
The two most prescribed weight loss peptides work through different receptor mechanisms. Here is how they compare on efficacy, safety, and access.
Read article →Compounded Semaglutide in 2026: FDA Rules, Safety, and What You Should Know
Compounded semaglutide occupies a regulatory gray zone in 2026. The FDA ended the national semaglutide shortage in February 2025, fundamentally changing the legal basis under which compounding pharmacies had been producing it. Here is what the FDA guidance says and what consumers should understand about safety and access.
Read article →After Ozempic: The Next Generation of GLP-1 Weight Loss Peptides
The GLP-1 pipeline extends well beyond current options. Triple agonists, oral non-peptide compounds, and muscle-sparing formulations are in late-stage trials.
Read article →How to Read a Peptide Certificate of Analysis (COA)
A Certificate of Analysis is the single most important document for evaluating peptide quality, yet most people never learn how to read one. This guide breaks down every section of a real COA and explains what the numbers actually mean.
Read article →12 Warning Signs of Unreliable Peptide Vendors
Not all peptide vendors are created equal. This checklist covers the 12 most common warning signs that a vendor may not be providing the quality, transparency, or safety standards that researchers should expect.
Read article →Peptide Drug Interactions: What Your Doctor Needs to Know
Peptides bypass many traditional drug metabolism pathways, but that does not make them interaction-free. This guide covers known and theoretical interaction risks with common medication classes.
Read article →Peptide Storage and Shelf Life: When to Use It and When to Toss It
Improper storage is one of the most common reasons peptides lose potency or become unusable. This guide covers storage temperatures, degradation mechanisms, and practical timelines for lyophilized and reconstituted peptides.
Read article →How to Talk to Your Doctor About Peptide Therapy
Bringing up peptide therapy with a physician can feel awkward. Many doctors have limited exposure to compounded peptides, and patients often worry about being dismissed. This guide provides a structured approach to having a productive, evidence-grounded conversation with your healthcare provider.
Read article →Peptide Legality in 2026: FDA Rules, State Laws, and What You Can Buy
The legal landscape for peptides in 2026 is layered and shifting. This guide breaks down the full picture — from FDA-approved drugs to compounded preparations to research chemicals — so you can understand what is legal, what is restricted, and where the lines are drawn.
Read article →Blood Work Before and During Peptide Therapy: Which Labs You Need
Lab work is the foundation of safe peptide therapy. Without baseline markers, you cannot meaningfully assess whether a peptide protocol is helping, doing nothing, or causing harm. This guide covers which panels to request, why each marker matters, and how often to retest.
Read article →Peptides and Sleep: What Research Shows About DSIP, CJC-1295, and Ipamorelin
Several peptides have attracted research interest for their potential connections to sleep physiology. This article reviews the preclinical and clinical evidence for DSIP, CJC-1295, and ipamorelin as they relate to sleep quality and architecture.
Read article →Peptides and Weight Loss: GLP-1s, AOD-9604, and HGH Fragment 176-191 Research Overview
Several peptides have been studied for their potential roles in weight management, ranging from FDA-approved GLP-1 receptor agonists to research-stage compounds like AOD-9604 and HGH fragment 176-191. This overview examines what the clinical and preclinical evidence actually shows.
Read article →Best Peptides for Recovery: Ranked by Evidence for Healing and Repair
A ranked look at the peptides most studied for recovery and tissue repair, from BPC-157 and TB-500 to copper peptides and growth hormone secretagogues. Evidence levels, mechanisms, and honest limitations.
Read article →Cognitive Peptides: Semax, Selank, Dihexa, and Nootropic Peptides for Brain Health
A small but growing body of research has examined peptides for their potential effects on memory, focus, neuroplasticity, and neuroprotection. This article reviews the evidence for Semax, Selank, Dihexa, and related cognitive peptides, along with important context about the current state of the science.
Read article →Best Peptides for Anti-Aging and Skin: What the Research Shows
An evidence-ranked review of the peptides most studied for anti-aging and skin health, from copper peptides and telomere research to mitochondrial-targeted compounds.
Read article →Peptides and Women's Health: Hormonal Context, Safety, and What Research Exists
Peptide research has historically been conducted predominantly in male subjects or mixed-sex animal models. This article explores what is known — and what remains poorly studied — about how peptides interact with female physiology, including hormonal context and safety considerations.
Read article →12 Peptide Myths Debunked: What the Evidence Actually Says
Peptides have attracted enormous attention in both research and wellness communities, and with that attention comes a growing body of misinformation. From claims that peptides are just another name for steroids to the belief that they work overnight, misconceptions can lead to unrealistic expectations or genuinely unsafe decisions. Here are 12 of the most persistent peptide myths, examined against what the scientific literature actually supports.
Read article →Peptide Cycling Guide: Why Cycling Matters, Research Protocol Patterns, and Tolerance
Peptide cycling — alternating periods of use with periods of rest — is a common feature of research protocols and clinical discussions. This guide explains the biological rationale for cycling, how receptor desensitization works, and what published research protocols suggest about on/off patterns.
Read article →Advanced Peptide Dosing Education: Research Protocols vs. Anecdotal Use
Published research protocols often look quite different from the dosing approaches that circulate in online communities. This educational overview examines how researchers approach peptide dosing, why weight-based and fixed dosing differ, and what the gap between research and anecdotal protocols means for interpreting efficacy claims.
Read article →The Wolverine Stack: What Research Says About BPC-157 and TB-500 Combined
The "Wolverine stack" combining BPC-157 and TB-500 is among the most discussed peptide protocols in research communities. This article examines the mechanisms of each peptide, the biological rationale for combining them, and the current state of the evidence — including what the research does and does not support.
Read article →TRT and Peptides: What Men Considering Testosterone Replacement Should Know
Men considering or currently undergoing testosterone replacement therapy increasingly encounter discussions of peptides as complementary protocols. This article provides educational context on how different peptide classes interact with the androgen axis and what the research suggests about combined approaches.
Read article →How Much Does Peptide Therapy Cost? A Realistic Pricing Breakdown
The cost of peptide therapy is one of the most opaque aspects of the entire space. Monthly prices can range from under $100 to over $1,500 depending on where you source compounds, which peptides you use, and whether you go through a clinical provider or a compounding pharmacy with a prescription. The lack of price transparency creates confusion and, in some cases, exploitation. This article provides a realistic accounting of what peptide therapy actually costs across different access points.
Read article →BPC-157 in 2026: Latest Research Updates, Clinical Trial Status, and Evidence Review
BPC-157 research has continued to generate publications while clinical translation has remained limited. This 2026 update reviews the current state of the evidence, clinical trial status, regulatory considerations, and what researchers and clinicians are saying about this peptide's prospects.
Read article →TB-500 (Thymosin Beta-4) Complete Guide: Mechanism, Research, and Safety
TB-500, a synthetic fragment of Thymosin Beta-4, has attracted significant research interest for tissue repair, recovery, and regeneration. This comprehensive guide covers its molecular mechanism, what the research actually shows, and important safety context.
Read article →Epithalon (Epitalon) Research Guide: Telomerase, Longevity, and What the Studies Show
Epithalon is a synthetic tetrapeptide that has attracted research interest for its potential effects on telomerase activation, pineal gland function, and longevity. This guide examines the published evidence — including what the studies actually show and the important limitations of the current research base.
Read article →NAD+ and Peptides: How NMN, NR, and Related Compounds Connect to Peptide Research on Aging
NAD+ precursors like NMN and NR and research peptides like Epithalon and GHK-Cu address some of the same biological processes associated with aging. This article explores where these research areas converge, what the evidence shows for each, and how they may relate to cellular health.
Read article →CJC-1295 and Ipamorelin Stack: GH Secretagogue Mechanisms, Research Protocols, and Safety
CJC-1295 and ipamorelin are growth hormone secretagogues that are often combined based on their complementary mechanisms. This guide covers what each peptide does, what the published human research shows, and important safety considerations for this commonly discussed stack.
Read article →Are Injectable Peptides Safe? What the 2026 Research Actually Shows
As injectable peptides grow in popularity, a University of Queensland academic analysis published in April 2026 asks the exact question new users ask first: what evidence do we have they're safe for humans? This article examines what the 2026 research shows — and where the gaps remain.
Read article →Best Peptides for Muscle Growth: Evidence, Mechanisms, and WADA Status
An evidence-based review of growth hormone secretagogues and other peptides studied for muscle growth, including their mechanisms, research findings, limitations, and status on the WADA prohibited list.
Read article →BPC-157 for Gut Health: What the Research Says About IBS, Leaky Gut, and Digestive Repair
BPC-157 is a synthetic peptide derived from a protective protein in gastric juice. Its origins in the digestive system have driven substantial preclinical research into gut barrier integrity, NSAID-induced damage protection, and intestinal healing. This article examines what that research actually shows, where the evidence gaps remain, and why gastric origin alone does not prove gastrointestinal efficacy.
Read article →Peptide Cycling and Desensitization: Do You Need to Take Breaks?
One of the most debated questions in peptide research is whether you need to cycle off periodically to avoid losing effectiveness. The answer depends on the specific peptide, the receptor system it targets, and the biological mechanism involved. Understanding the difference between tachyphylaxis and receptor downregulation is essential for making evidence-informed protocol decisions.
Read article →Peptide Dosing Math: How to Calculate Concentrations After Reconstitution
Reconstitution math is one of the most critical practical skills for anyone working with lyophilized peptides in a research setting. Errors in concentration calculations can result in doses that are dramatically too high or too low, with consequences ranging from wasted compound to genuine safety concerns. This guide walks through the formulas, the unit conversions, and worked examples step by step.
Read article →Peptide Therapy vs TRT vs HGH: How These Approaches Differ
Peptide therapy, testosterone replacement therapy (TRT), and growth hormone (HGH) injections are frequently discussed in the same conversations about aging, performance, and body composition. But these three approaches work through fundamentally different mechanisms, carry different risk profiles, and sit at very different points on the evidence spectrum. Understanding those differences is essential for anyone trying to make sense of the hormone optimization landscape.
Read article →Peptides for Surgery Recovery: What Patients Are Asking
Surgical patients are increasingly asking about peptides for recovery — and increasingly finding recommendations in online forums rather than from their surgical teams. BPC-157, TB-500, and GHK-Cu are the most commonly discussed compounds. This article examines what the preclinical research actually supports, why surgeons are rarely the ones recommending these compounds, and the important safety considerations that forum discussions tend to skip.
Read article →Topical vs Injectable Peptides for Skin: Which Delivery Method Works?
Peptides for skin health — particularly GHK-Cu — are available in both topical creams and injectable formulations. These two delivery routes are not interchangeable. The skin is a barrier organ designed to keep molecules out, and a peptide that works when injected may not reach its target when applied to the surface. This article examines what determines whether a peptide can penetrate skin, what emerging delivery technologies are attempting to solve, and how to evaluate the two approaches honestly.
Read article →Best Strength-Training Apps for Peptide Users Tracking Gains
Users tracking peptide protocols alongside strength training may want a lifting log that captures RPE, respects on-device privacy, and exports cleanly for multi-month review. We compare LiftProof, Hevy, and Strong on those criteria. This article is informational only — it is about tools, not protocols.
Read article →Peptide Protocols + Lifting Tracking — Tools Experimenters Use
No single app handles peptide protocol tracking + lifting + vitals + narrative — the right framing is a composed stack. We walk through the layers and the privacy-first tools we use for each: LiftProof for lifts, PeptideTracker or Prova for protocols, Apple Health for vitals, Notion for narrative.
Read article →GLP-1 Agonists and Mental Health: What the 2026 Swedish Cohort Found, and What It Does Not Say
A national Swedish registry analysis of 95,490 adults with pre-existing depression or anxiety found that semaglutide was associated with a 42% lower risk of worsening mental illness during active treatment periods compared to non-treatment periods. Here is what the Lancet Psychiatry data shows, why the effect differed by GLP-1 agent, and what the data does not — and cannot — say about using GLP-1 drugs for mood.
Read article →Semaglutide in Adults Over 65: What the ECO 2026 STEP Pooled Analysis Showed
A pooled subgroup analysis of the STEP semaglutide trials, presented by Prof Luca Busetto at the European Congress on Obesity in May 2026, reported a mean weight loss of 15.4% at 68 weeks among 358 adults aged 65 and older — roughly the same magnitude seen in younger participants. The safety signal, however, was non-trivial: serious adverse events occurred in 19.0% of the semaglutide arm compared with 12.7% of placebo. This article walks through what the analysis pooled, where the data is strong, and where it should be read with care.
Read article →